Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mesoblast Limited (MSB.AX)
Melbourne, VIC, AU
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.42% | +0.94% | +0.94% | -4.46% | -21.03% | -21.32% | +33.75% | +122.37% | +15.05% | +15.68% | +245.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+191.4% ★ Q2'25: +458.6% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%-0.3% Q2'25: +13.8% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-578.6% Q2'25: -63.6% (vs Q2'24)
-
EBIT margin Biotechnology: +0.0%-465.5% Q2'25: -302.4% (vs Q2'24)
-
ROIC Biotechnology: -16.1%-14.2% ★ Q2'25: -14.6% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+15.8% Q2'25: +13.5% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.74× Q2'25: -1.72× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 7 Rev. Ana. 3 EPS Ana. |
Jun 2027 7 Rev. Ana. 4 EPS Ana. |
Jun 2028 5 Rev. Ana. 4 EPS Ana. |
Jun 2029 2 Rev. Ana. 1 EPS Ana. |
Jun 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
23.75M
est: 22.05M (+7.7%)
|
42.55M
est: 20.67M (+105.9%)
|
2.41M
est: 4.24M (-43.1%)
|
17.34M
est: 16.32M (+6.3%)
|
16.72M
est: 16.25M (+2.9%)
|
32.16M
est: 44.46M (-27.7%)
|
7.46M
est: 27.23M (-72.6%)
|
10.21M
est: 13.84M (-26.2%)
|
7.50M
est: 8.39M (-10.5%)
|
5.90M
est: 7.49M (-21.2%)
|
17.20M
est: 17.40M (-1.2%)
|
120.65M
112.02M – 140.03M
+593.3% YoY
|
206.75M
137.34M – 307.92M
+71.4% YoY
|
398.10M
302.95M – 545.03M
+92.6% YoY
|
874.25M
665.30M – 1.20B
+119.6% YoY
|
852.11M
648.46M – 1.17B
-2.5% YoY
|
| EBITDA |
-90.19M
est: -22.05M (-309.1%)
|
-28.07M
est: -20.67M (-35.8%)
|
-87.16M
est: -4.24M (-1,957.2%)
|
-74.69M
est: -16.32M (-357.7%)
|
-84.54M
est: -16.25M (-420.1%)
|
-68.97M
est: -44.46M (-55.1%)
|
-84.65M
est: -27.23M (-210.9%)
|
-76.57M
est: -13.84M (-453.1%)
|
-58.55M
est: -8.39M (-598.3%)
|
-56.08M
est: -7.49M (-648.4%)
|
-73.66M
est: -17.40M (-323.3%)
|
-120.65M
-140.03M – -112.02M
-593.3% YoY
|
-206.75M
-307.92M – -137.34M
-71.4% YoY
|
-398.10M
-545.03M – -302.95M
-92.6% YoY
|
-874.25M
-1.20B – -665.30M
-119.6% YoY
|
-852.11M
-1.17B – -648.46M
+2.5% YoY
|
| EBIT |
-91.39M
est: -22.05M (-314.5%)
|
-90.82M
est: -20.67M (-339.5%)
|
-90.22M
est: -4.24M (-2,029.3%)
|
-64.15M
est: -16.32M (-293.1%)
|
-86.67M
est: -16.25M (-433.3%)
|
-72.64M
est: -44.46M (-63.4%)
|
-88.92M
est: -27.23M (-226.5%)
|
-74.30M
est: -13.84M (-436.6%)
|
-62.66M
est: -8.39M (-647.2%)
|
-57.97M
est: -7.49M (-673.7%)
|
-80.06M
est: -17.40M (-360.1%)
|
-120.65M
-140.03M – -112.02M
-593.3% YoY
|
-206.75M
-307.92M – -137.34M
-71.4% YoY
|
-398.10M
-545.03M – -302.95M
-92.6% YoY
|
-874.25M
-1.20B – -665.30M
-119.6% YoY
|
-852.11M
-1.17B – -648.46M
+2.5% YoY
|
| Net Income |
-119.37M
est: -231.43M (+48.4%)
|
-4.13M
est: -194.27M (+97.9%)
|
-76.82M
est: -84.53M (+9.1%)
|
-35.29M
est: -105.07M (+66.4%)
|
-89.80M
est: -206.84M (+56.6%)
|
-77.94M
est: -134.23M (+41.9%)
|
-98.81M
est: -150.74M (+34.4%)
|
-91.35M
est: -120.88M (+24.4%)
|
-81.89M
est: -122.56M (+33.2%)
|
-87.96M
est: -58.65M (-50.0%)
|
-102.14M
est: -66.71M (-53.1%)
|
-40.06M
-42.18M – -17.07M
+40.0% YoY
|
16.39M
-3.68M – 19.60M
+140.9% YoY
|
138.01M
-12.65M – 166.30M
+742.2% YoY
|
157.02M
108.24M – 232.36M
+13.8% YoY
|
361.26M
249.02M – 534.60M
+130.1% YoY
|
| SGA |
65.38M
est: 121.59M (-46.2%)
|
52.26M
est: 113.97M (-54.1%)
|
35.07M
est: 23.36M (+50.1%)
|
27.42M
est: 89.99M (-69.5%)
|
36.98M
est: 89.63M (-58.7%)
|
50.92M
est: 245.18M (-79.2%)
|
63.59M
est: 150.17M (-57.7%)
|
57.97M
est: 76.35M (-24.1%)
|
53.11M
est: 46.24M (+14.8%)
|
23.63M
est: 41.32M (-42.8%)
|
39.31M
est: 95.96M (-59.0%)
|
665.33M
617.78M – 772.21M
+593.3% YoY
|
1.14B
757.42M – 1.70B
+71.4% YoY
|
2.20B
1.67B – 3.01B
+92.6% YoY
|
4.82B
3.67B – 6.60B
+119.6% YoY
|
4.70B
3.58B – 6.43B
-2.5% YoY
|
| EPS |
-0.22
est: -0.20 (-8.6%)
|
-0.01
est: -0.17 (+95.5%)
|
-0.14
est: -0.07 (-89.2%)
|
-0.07
est: -0.09 (+28.7%)
|
-0.17
est: -0.18 (+6.1%)
|
-0.14
est: -0.12 (-19.1%)
|
-0.16
est: -0.13 (-21.2%)
|
-0.14
est: -0.11 (-32.3%)
|
-0.11
est: -0.11 (-2.5%)
|
-0.09
est: -0.05 (-70.3%)
|
-0.09
est: -0.06 (-52.7%)
|
-0.03
-0.04 – -0.01
+52.1% YoY
|
0.01
0.00 – 0.02
+120.2% YoY
|
0.06
-0.01 – 0.15
+928.1% YoY
|
0.14
0.09 – 0.20
+135.5% YoY
|
0.32
0.22 – 0.47
+130.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.76% | 663.6K | 0.55% |
| 2 | BetaShares - Australian Sustainability Leaders ETF FAIR.AX | 0.52% | 3.87M | 0.49% |
| 3 | Vanguard MSCI Australian Small Companies Index ETF VSO.AX | 0.33% | 2.62M | 0.30% |
| 4 | BetaShares - Australian Ex-20 Portfolio Diversifier ETF EX20.AX | 0.20% | 908.9K | 0.25% |
| 5 | BetaShares - Geared Australian Equities Complex ETF GEAR.AX | 0.17% | 758.6K | 0.78% |
| 6 | BetaShares - Managed Risk Australian Shares Complex ETF AUST.AX | 0.08% | 15.1K | 0.49% |
| 7 | iShares Core S&P/ASX 200 ETF IOZ.AX | 0.08% | 4.97M | 0.05% |
| 8 | Vanguard Australian Shares Index ETF VAS.AX | 0.08% | 13.45M | 0.07% |
| 9 | Goldman Sachs Innovate Equity ETF GINN | 0.08% | 158.6K | 0.50% |
| 10 | BetaShares - Australia 200 ETF A200.AX | 0.07% | 5.05M | 0.04% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Silviu Itescu FACP FACRA FRACP MBBS | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director | 2M | — |
| Eric A. Rose | Chief Medical Officer & Executive Director | 1M | — |
| Geraldine Storton | Head of Regulatory Affairs & Quality Management | — | female |
| James Michael O'Brien | Chief Financial Officer | — | male |
| Daniel Devine | Head of Special Projects | — | male |
| Marcelo Santoro | Chief Commercial Officer | — | male |
| Paul Hughes BPHARM | Global Head of Corporate Communications & Joint Company Secretary | — | male |
| Paul J. Simmons | Scientific Advisor to the Chief Executive Officer | — | — |
| Peter T. Howard | General Counsel & Corporate Executive | — | male |
| Justin Horst | Head of Manufacturing | — | male |
| Fiona See | Senior Vice President & Head of Translational Research | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MSB.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
